News List
Holiday Notice of Mid-Autumn Festival
2019-09-11
To all departments and all employees:According to the related provisions on national holidays & the actual situation
CPhI North America 2020 in Philadelphia USA Booth#1506
2019-08-26
FluoroPharm will exhibit CPhI North America 2020 in Pennsylvania Convention Center,Philadelphia, PA, USA, May 5-7,2020.O
FDA approves third oncology drug that targets a key genetic driver of cancer, rather than a specific type of tumor
2019-08-19
The U.S. Food and Drug Administration today granted accelerated approval to Rozlytrek (entrectinib), a treatment for adu
The 150 millionth chemical substance was born!
2019-08-07
According to the American Chemical and Engineering News (C&EN), the American Chemical Abstracts Service (CAS) regist
FDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer
2019-07-12
Novartis today announced the US Food and Drug Administration (FDA) has approved Piqray® (alpelisib) in combination with
New drug delivery method, FDA approved a new epilepsy treatment
2019-06-29
UCB announced that the USFDA has approved Nayzilam (midazolam) nasal spray for the acute treatment of seizure clusters p
Holiday Notice of Dragon Boat Festival
2019-06-01
To all departments and employees:According to the related national legal & the actual situation of our company, we i
Long-term anti-AIDS, Combination of two schemes submits application
2019-05-29
On April 29, 2019，the anti-AIDS long-acting two-party “cabotegravir + Ripirilin”submitted to the FDA for listing applica
For the initial treatment of HIV patients, the FDA approved the first dual-agent combination therapy
2019-04-27
Today, the US FDA announced that it has approved the listing of the antiviral therapy Dovato (dolutegravir and lamivudin
Novartis‘s Multiple sclerosis Innovative drug approved
2019-03-29
Recently, US FDA announced approved the listing of Mayzent (siponimod) developed by Novartis, for the treatment of recur